Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.

Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P.

Biol Blood Marrow Transplant. 2019 Apr;25(4):683-688. doi: 10.1016/j.bbmt.2018.12.141. Epub 2018 Dec 21.

PMID:
30579965
2.

Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups.

Scott EC, Hari P, Kumar S, Fraser R, Davila O, Shah N, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble RT, Lazarus H, Solh M, Usmani SZ, Kanate AS, Saad A, Chhabra S, Gergis U, Cerny J, Kyle RA, Lee C, Kindwall-Keller T, Assal A, Hildebrandt GC, Holmberg L, Maziarz RT, Nishihori T, Seo S, Kumar S, Mark T, D'Souza A.

Biol Blood Marrow Transplant. 2018 Dec;24(12):2443-2449. doi: 10.1016/j.bbmt.2018.08.013. Epub 2018 Aug 22.

PMID:
30142419
3.

Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.

González-Calle V, Slack A, Keane N, Luft S, Pearce KE, Ketterling RP, Jain T, Chirackal S, Reeder C, Mikhael J, Noel P, Mayo A, Adams RH, Ahmann G, Braggio E, Stewart AK, Bergsagel PL, Van Wier SA, Fonseca R.

Ann Hematol. 2018 Aug;97(8):1453-1462. doi: 10.1007/s00277-018-3316-7. Epub 2018 Apr 6.

PMID:
29623394
4.

Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time.

Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, Kharfan-Dabaja M, Freytes C, Hashmi S, Hildebrandt G, Holmberg L, Kyle R, Lazarus H, Lee C, Mikhael J, Nishihori T, Tay J, Usmani S, Vesole D, Vij R, Wirk B, Krishnan A, Gasparetto C, Mark T, Nieto Y, Hari P, D'Souza A.

Leukemia. 2018 Apr;32(4):986-995. doi: 10.1038/leu.2017.331. Epub 2017 Nov 16.

5.

Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant.

Hari PN, Zhang MJ, Roy V, Pérez WS, Bashey A, To LB, Elfenbein G, Freytes CO, Gale RP, Gibson J, Kyle RA, Lazarus HM, McCarthy PL, Milone GA, Pavlovsky S, Reece DE, Schiller G, Vela-Ojeda J, Weisdorf D, Vesole D.

Leukemia. 2009 Aug;23(8):1528-34. doi: 10.1038/leu.2009.61. Epub 2009 Mar 26.

6.

The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients.

Bila J, Jelicic J, Dencic Fekete M, Trajkovic G, Sretenovic A, Perunicic Jovanovic M, Antic D, Mihaljevic B.

Oncol Res Treat. 2017;40(10):616-620. doi: 10.1159/000478935. Epub 2017 Sep 19.

8.

High serum lactate dehydrogenase predicts an unfavorable outcome in Chinese elderly patients with multiple myeloma.

Gu Y, Yuan YH, Xu J, Shi QL, Qu XY, Guo R, Bai H, Xu JD, Li JY, Chen LJ.

Oncotarget. 2017 Jul 18;8(29):48350-48361. doi: 10.18632/oncotarget.16237.

9.

[Long-term follow-up of multiple myeloma after autologous hematopoietic stem cell transplantation: a single center results].

Sui WW, Zou DH, An G, Yi SH, Deng SH, Huang WY, Wang TY, Li J, Liu H, Fu MW, Lyu R, Liu W, Xu Y, Li ZJ, Zhao YZ, Qiu LG.

Zhonghua Xue Ye Xue Za Zhi. 2017 Jun 14;38(6):499-504. doi: 10.3760/cma.j.issn.0253-2727.2017.06.007. Chinese.

PMID:
28655093
10.

Predictive value of post-transplant bone marrow plasma cell percent in multiple myeloma patients undergone autologous transplantation.

Hwang IH, Chung JS, Shin HJ, Choi YJ, Song MK, Seol YM, Cho GJ, Choi BG, Choi MK, Choi BK, Ahn KH, Shin KH, Lee HS, Nam HS, Hwang JM.

Korean J Intern Med. 2011 Mar;26(1):76-81. doi: 10.3904/kjim.2011.26.1.76. Epub 2011 Mar 2.

11.

LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.

Chim CS, Sim J, Tam S, Tse E, Lie AK, Kwong YL.

Eur J Haematol. 2015 Apr;94(4):330-5. doi: 10.1111/ejh.12434. Epub 2014 Oct 18.

PMID:
25135740
12.

[Prognostic value of the revised international staging system for newly diagnosed multiple myeloma patients].

Lu J, Du J, Fu WJ, He HY, Li L, Li R, Zhou LL, Jiang H, Hou J.

Zhonghua Xue Ye Xue Za Zhi. 2017 Jun 14;38(6):475-479. doi: 10.3760/cma.j.issn.0253-2727.2017.06.003. Chinese.

PMID:
28655089
13.

Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.

Zhang BL, Zhou J, Lin QD, Liu YZ, Zhang YL, Gui RR, Song YP, Fang BJ.

Artif Organs. 2019 Apr 10. doi: 10.1111/aor.13468. [Epub ahead of print]

PMID:
30972806
14.

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P.

J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3.

15.

Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival.

Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, Seo S, Ramanathan M, Usmani SZ, Gasparetto C, Mark TM, Nieto Y, Hari P.

Biol Blood Marrow Transplant. 2018 Mar;24(3):478-485. doi: 10.1016/j.bbmt.2017.10.024. Epub 2017 Oct 24.

16.

Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma.

Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H, Suzuki K, Isoda A, Matsumoto M, Sawamura M, Sunami K, Takezako N, Hagiwara S, Kuroda Y, Chou T, Nagura E, Shimizu K.

Ann Hematol. 2019 Jul;98(7):1703-1711. doi: 10.1007/s00277-019-03702-1. Epub 2019 May 2.

PMID:
31049648
17.

Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents.

Romano A, Parrinello NL, Consoli ML, Marchionni L, Forte S, Conticello C, Pompa A, Corso A, Milone G, Di Raimondo F, Borrello I.

Ann Hematol. 2015 Nov;94(11):1875-83. doi: 10.1007/s00277-015-2462-4. Epub 2015 Jul 31.

18.

[Efficacy and prognostic factors of induction therapy combined with autologous stem cell transplantation in 201 patients with multiple myeloma].

Jin L, Fu W, Xi H, Zhang C, Du J, He H, Jiang H, Zeng T, Fan J, Zhou L, Chang H, Hou J.

Zhonghua Xue Ye Xue Za Zhi. 2016 Jan;37(1):14-9. doi: 10.3760/cma.j.issn.0253-2727.2016.01.003. Chinese.

PMID:
26876247
19.

[Clinical Application of R-ISS Staging System in 412 Newly Diagnosed Patients with Multiple Myeloma].

Chen HM, Wei W, Peng R, Shi HT, Chen XL, Wu LX, Zhou N, Zhou F.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Feb;27(1):110-114. doi: 10.7534/j.issn.1009-2137.2019.01.018. Chinese.

PMID:
30738456
20.

Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.

Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P.

Biol Blood Marrow Transplant. 2017 Feb;23(2):269-277. doi: 10.1016/j.bbmt.2016.11.011. Epub 2016 Nov 15.

Supplemental Content

Support Center